Filtered By:
Cancer: Lung Cancer

This page shows you your search results in order of relevance. This is page number 5.

Order by Relevance | Date

Total 15396 results found since Jan 2013.

Corrigendum Traditional Chinese medicine, Fuzheng Kang ‑Ai decoction, inhibits metastasis of lung cancer cells through the STAT3/MMP9 pathway
Mol Med Rep. 2021 Aug;24(2):600. doi: 10.3892/mmr.2021.12244. Epub 2021 Jun 29.ABSTRACTFollowing the publication of the above article, an interested reader drew to the authors' attention that various of the data panels shown for the cell migration assay experiments in Figs. 2B and 3 appeared to show overlapping regions, such that they were not generated from discretely performed experiments.The authors have re-examined their original data, and realize that the figures in question were assembled incorrectly. In addition, the authors have also realized that certain of the western blotting data panels in Figs. 5 and 6 had lik...
Source: Molecular Medicine Reports - June 29, 2021 Category: Molecular Biology Authors: Longmei Li Sumei Wang Xiaobin Yang Shunqin Long Shujing Xiao Wanyin Wu Swei Sunny Hann Source Type: research

The Effect of Terpenoid Natural Chinese Medicine Molecular Compound on Lung Cancer Treatment
Evid Based Complement Alternat Med. 2021 Dec 16;2021:3730963. doi: 10.1155/2021/3730963. eCollection 2021.ABSTRACTAmong all malignant tumors in the whole universe, the incidence and mortality of lung cancer disease rank first. Especially in the past few years, the occurrence of lung cancer in the urban population has continued to increase, which seriously threatens the lives and health of people. Among the many treatments for lung cancer, chemotherapy is the best one, but traditional chemotherapy has low specificity and drug resistance. To address the above issue, this study reviews the five biological pathways that common...
Source: Evidence-based Complementary and Alternative Medicine - December 27, 2021 Category: Complementary Medicine Authors: Heng Sun Lijia Zhang Bowen Sui Yu Li Jun Yan Peng Wang Ye Wang Songjiang Liu Source Type: research

Treatment of Lung Cancer with Orally Administered Chinese Herbal Medicine: An Evidence Map between 1970 –2020
ConclusionsCHM has staged and therapeutic advantages in treating lung cancer. The overall methodological quality is poor, and the level of evidence requires improvement. It is necessary to carry out large-scale, standardized, and higher-quality research in the superior and weak areas of CHM treatment of lung cancer.
Source: Chinese Journal of Integrative Medicine - March 3, 2022 Category: Internal Medicine Source Type: research

Retrospective Clinical Study on Integrated Chinese and Western Medicine in Treatment of Limited-Stage Small Cell Lung Cancer
ConclusionThe combination treatment of CM and WM with continuing oral administration of CM treatment after the first-line chemoradiotherapy for LS-SCLC patients produced better prognosis, lower risks of progression, and longer survival than the WM treatment alone. (Registration No. ChiCTR2200056616)
Source: Chinese Journal of Integrative Medicine - January 6, 2023 Category: Internal Medicine Source Type: research

Verifying the Role of Surgical Pathologists in the Precision Medicine of Lung Cancer.
PMID: 23276149 [PubMed - as supplied by publisher]
Source: Archives of Pathology and Laboratory Medicine - December 31, 2012 Category: Laboratory Medicine Authors: Cagle PT, Olsen RJ Tags: Arch Pathol Lab Med Source Type: research

Molecular profiling in non-small cell lung cancer: a step toward personalized medicine.
CONCLUSIONS: There are multiple mechanisms involved in the pathogenesis of lung cancer, which operate in parallel and involve pathways of activation and inhibition of various cellular events. Further research is essential to characterize the histologic and mutational profiles of lung carcinomas, which will ultimately translate into improved and more personalized therapeutic management of patients with lung cancer. PMID: 23544937 [PubMed - in process]
Source: Archives of Pathology and Laboratory Medicine - April 1, 2013 Category: Laboratory Medicine Authors: Raparia K, Villa C, DeCamp MM, Patel JD, Mehta MP Tags: Arch Pathol Lab Med Source Type: research

Yearly lung cancer screenings
The U.S. Preventive Services Task Force recently issued a recommendation that people older than 55 who have smoked an average of one pack of cigarettes a day for at least 30 years be screened for lung cancer yearly. "Sound Medicine" presents two experts who will debate the risks and benefits of yearly lung cancer screenings. Fred Duncan, director and CEO of the Little Red Door Cancer Agency in Ind....
Source: Sound Medicine - October 19, 2013 Category: Global & Universal Authors: Sound Medicine Source Type: news

Bayesian two-step Lasso strategy for biomarker selection in personalized medicine development for time-to-event endpoints
Abstract: Clinical trial designs for targeted therapy development are progressing toward the goal of personalized medicine. Motivated by the need of ongoing efforts to develop targeted agents for lung cancer patients, we propose a Bayesian two-step Lasso procedure for biomarker selection under the proportional hazards model. We seek to identify the key markers that are either prognostic or predictive with respect to treatment from a large number of biomarkers. In the first step of our two-step strategy, we use the Bayesian group Lasso to identify the important marker groups, wherein each group contains the main effect of a...
Source: Contemporary Clinical Trials - October 23, 2013 Category: Radiology Authors: Xuemin Gu, Guosheng Yin, J. Jack Lee Tags: Special Section: Clinical Trials for Personalized Medicine; Guest Editors: Liang Fang, Mei-Chiung Shih, Guosheng Yin, Consolato Maria Sergi, and Say Beng Tan Source Type: research

Tobacco usage over the past 50 years
The first surgeon general's smoking and health report 50 years ago stated that smoking causes lung cancer. Michael Fiore, M.D., MPH, MBA, recently co-wrote an article about the report's effect on society. Dr. Fiore joins "Sound Medicine" to comment on the smoking culture before the report was published, the ramifications of the report, and current efforts to eliminate tobacco usage. Another r....
Source: Sound Medicine - February 15, 2014 Category: Global & Universal Authors: Sound Medicine Source Type: news

Cholinergic Receptors as Target for Cancer Therapy in a Systems Medicine Perspective.
Abstract Epithelial cells not innervated by cholinergic neurons express nicotinic and muscarinic acetylcholine (ACh) receptors (nAChR, mAChR). nAChR and mAChR are components of the auto-/paracrine-regulatory loop of non-neuronal ACh release. The cholinergic control of non-neuronal cells may be mediated by different effects (synergistic, additive, or reciprocal) triggered by these receptors. The ionic events (Ca+2 influx) are generated by the ACh-opening of nAChR channels, while the metabolic events by ACh-binding to G-protein-coupled mAChR. Effective inter- and intracellular signaling is crucial for valuable cance...
Source: Current Molecular Medicine - October 15, 2014 Category: Molecular Biology Authors: Russo P, Bufalo AD, Salinaro G, Fini M, Cesario A Tags: Curr Mol Med Source Type: research

Towards the goal of personalized medicine in gastric cancer--time to move beyond HER2 inhibition. Part II: Targeting gene mutations and gene amplifications and the angiogenesis pathway.
Authors: Lee J, Ou SH Abstract Gastric cancer is the second leading cancer cause of death globally. Apart from the successful targeting of HER2 over-expression in gastric cancer (GC) with trastuzumab, other targeted therapies in GC have fallen short or still in early clinical development. While HER2 over-expression accounts for up to 20% of GC, other potential actionable driver mutations occur at a much lower frequency in GC. In this review we describe some of the more interesting genetic aberrations including driver mutations in gastric cancer that have very potent inhibitors against them already in clinical devel...
Source: Discovery Medicine - November 14, 2014 Category: Research Tags: Discov Med Source Type: research

Towards the goal of personalized medicine in gastric cancer--time to move beyond HER2 inhibition. Part I: Targeting receptor tyrosine kinase gene amplification.
Authors: Lee J, Ou SH Abstract Gastric cancer is the second leading cancer cause of death globally. Apart from the successful targeting of HER2 over-expression in gastric cancer (GC) with trastuzumab, other targeted therapies in GC have fallen short or still in early clinical development. While HER2 over-expression accounts for up to 20% of GC, other potential actionable driver mutations occur a much lower frequency in GC. In this review we describe some of the more interesting genetic aberrations including driver mutations in gastric cancer that have very potent inhibitors against them already in clinical developm...
Source: Discovery Medicine - November 14, 2014 Category: Research Tags: Discov Med Source Type: research

Challenges and Opportunities for Identifying Non–Small Cell Lung Cancer Biomarkers Using Bronchoscopy
Non–small cell lung cancer is no longer viewed as a single disease, but a constellation of cancer types that benefit from different treatments. Advancements in the identification of driver mutations with specific Food and Drug Administration–regulated molecular tests have been approved for matching the right treatment to the right patient. These biomarkers, referred to as theranostic biomarkers, because of their ability to support treatment decisions and predict a clinical response are changing the way oncologists formulate non–small cell lung cancer treatment plans. Currently approved biomarker tests for lung cancer...
Source: Clinical Pulmonary Medicine - December 29, 2014 Category: Respiratory Medicine Tags: Topics in Pulmonary Medicine Source Type: research